Tecentriq sets the bar in small-cell lung cancer

Adding Roche's checkpoint inhibitor Tecentriq to standard chemotherapy extended median overall survival in patients with small-cell lung cancer (SCLC) by two months compared to chemotherapy alone, according to updated study results released Tuesday at the World Conference on Lung Cancer in Toronto.